Risk factors for interstitial lung disease in rheumatoid arthritis: a cohort study from the KOBIO registry

被引:1
|
作者
Min, Hong Ki [1 ]
Kim, Se Hee [1 ,2 ]
Lee, Sang-Heon [3 ]
Kim, Hae-Rim [4 ]
机构
[1] Konkuk Univ, Med Ctr, Dept Internal Med, Div Rheumatol, Seoul, South Korea
[2] Kyung Hee Univ, Kyung Hee Univ Hosp Gangdong, Coll Med, Dept Rheumatol, Seoul, South Korea
[3] Konkuk Univ, Sch Med, Res Inst Med Sci, Div Rheumatol,Dept Internal Med,Med Ctr, Seoul, South Korea
[4] Konkuk Univ, Sch Med, Med Ctr, Div Rheumatol,Dept Internal Med,Res Inst Med Sci, 120-1 Neungdong Ro, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
biologics; DAS28; DMARDs; interstitial lung disease; rheumatoid arthritis; rheumatoid factor; AMERICAN-COLLEGE; EPIDEMIOLOGY; ABATACEPT; EVENTS;
D O I
10.1177/1759720X231218098
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Interstitial lung disease (ILD) is a critical extra-articular manifestation of rheumatoid arthritis (RA). However, little is known about the risk factors of RA-ILD.Objectives: Here, we examined the effect of demographic, clinical, therapeutic, and environmental factors on the incidence of ILD in RA patients using the Korean College of Rheumatology Biologics and Targeted Therapy (KOBIO) registry.Design: We used data from the KOBIO registry, a multi-center, prospective, observational cohort that included RA patients in South Korea.Methods: RA patients who used biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) or conventional synthetic (cs)DMARDs, and were enrolled in the KOBIO registry, were examined. Demographic, clinical, and radiographic characteristics, as well as medications, were recorded at baseline and annually thereafter. Kaplan-Meier curves and the log-rank test were used to compare the incidence of ILD between RA patients taking different b/tsDMARDs. Hazard ratios (HRs) were calculated by Cox regression analyses.Results: In total, 2492 patients (1967 in the b/tsDMARDs group and 525 in the csDMARDs group) were analyzed. The b/tsDMARDs group showed longer disease duration, higher erythrocyte sedimentation rate/C-reactive protein, and higher disease activity score-28 (DAS28) than the csDMARDs group. The incidence of ILD was significantly higher in those taking tumor necrosis factor inhibitors and abatacept than in those taking csDMARDs (log ranked p < 0.001). Multivariate Cox regression analysis identified older age (HR = 1.057, p = 0.001), male sex (HR = 2.824, p = 0.007), time-averaged DAS28 (HR = 2.241, p < 0.001), and rheumatoid factor titer (HR = 1.009, p = 0.007) as having a significantly increased HR for ILD occurrence.Conclusion: ILD is a rare but critical extra-articular symptom of RA patients. Therefore, RA patients with the above risk factors should be monitored carefully for ILD development.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Uncovering Risk Factors for Adverse Events and Infections in Rheumatoid Arthritis and Rheumatoid Arthritis with Interstitial Lung Disease Under Biologics or Targeted Synthetic DMARDs: Insights from the KOBIO Registry
    Kim, Ji-Won
    Jung, Ju-Yang
    Suh, Chang-Hee
    Kim, Hyoun-Ah
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2571 - 2573
  • [2] Uncovering risk factors for adverse events and infections in rheumatoid arthritis and rheumatoid arthritis with interstitial lung disease under treatment with biologics or targeted synthetic DMARDs: insights from the KOBIO Registry
    Kim, J.
    Shin, K.
    Jung, J.
    Suh, C.
    Lee, S.
    Kim, H.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2024, 42 (09) : 1781 - 1791
  • [3] Increased Risk of Lung Cancer in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Matched Cohort Study with Cancer Registry Linkage
    Brooks, Rebecca
    Yang, Yangyuna
    Roul, Punyasha
    Luedders, Brent
    Singh, Namrata
    Sauer, Brian
    Cannon, Grant
    Baker, Joshua
    Mikuls, Ted
    England, Bryant
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 3277 - 3279
  • [4] RISK FACTORS OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Kur-Zalewska, J.
    Tlustochowicz, M.
    Tlustochowicz, W.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 173 - 173
  • [5] Risk factors for rheumatoid arthritis-associated interstitial lung disease: a retrospective study
    Ben Tekaya, Aicha
    Mokaddem, Salma
    Athimini, Selma
    Kamoun, Hela
    Mahmoud, Ines
    Abdelmoula, Leila
    MULTIDISCIPLINARY RESPIRATORY MEDICINE, 2022, 17
  • [6] RISK AND RISK FACTORS OF MORTALITY IN RHEUMATOID ARTHRITIS PATIENTS WITH INTERSTITIAL LUNG DISEASE: A NATIONWIDE, POPULATION-BASED COHORT STUDY
    Chen, H. H.
    Chen, D. Y.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 555 - 555
  • [7] RISK FACTORS OF PATIENTS WITH INTERSTITIAL LUNG DISEASE COMPLICATED WITH RHEUMATOID ARTHRITIS
    Zhao, F.
    Zhang, W. D.
    Jiang, Y. L.
    Liu, W.
    Cao, J.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2020, 34 (01): : 221 - 226
  • [8] RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: RISK FACTORS
    Slouma, M.
    Bouzid, S.
    Metoui, L.
    Dhahri, R.
    Gharsallah, I.
    Louzir, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1380 - 1380
  • [9] Rheumatoid Arthritis-Associated Interstitial Lung Disease: Risk Factors For Disease Progression
    Chaichian, Y.
    Noth, I.
    Strek, M. E.
    Vij, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [10] Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis
    Mori, Shunsuke
    Koga, Yukinori
    Sugimoto, Mineharu
    RESPIRATORY MEDICINE, 2012, 106 (11) : 1591 - 1599